Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Boris Hadaschik

Showing results (141-150 of 269) with videos related to

Pageof 27
Sort By:
European Urology|February 4, 2023
Small Suspicious Lymph Nodes Detected on Ultrahigh-field Magnetic Resonance Imaging (MRI) in Patients with Prostate Cancer with High Risk of Nodal Metastases: The First In-patient Study on Ultrasmall Superparamagnetic Iron Oxide-enhanced 7T MRIAnsje Fortuin, Jack van Asten, Andor Veltien, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 23, 2026
PSMA-PET response under [<sup>177</sup>Lu]Lu-PSMA therapy: Comparison of RECIST, PERCIST, PPP, adapted PCWG4 and RECIP criteriaTugce Telli, Madeleine J Karpinski, Robert Seifert, et al.
International Journal of Cancer|July 4, 2017
Cyclin K dependent regulation of Aurora B affects apoptosis and proliferation by induction of mitotic catastrophe in prostate cancerSabrina Schecher, Britta Walter, Michael Falkenstein, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 1, 2014
Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapyChristian M Zechmann, Ali Afshar-Oromieh, Tom Armor, et al.
Prostate Cancer and Prostatic Diseases|November 14, 2024
Enhancing risk stratification models in localized prostate cancer by novel validated tissue biomarkersCsilla Olah, Fabian Mairinger, Michael Wessolly, et al.
Urologie (Heidelberg, Germany)|April 13, 2026
[Update of S3 guideline on metastatic prostate cancer-guideline recommendations and expert consensus]Marc-Oliver Grimm, Christian Gratzke, Boris Hadaschik, et al.
BJU International|January 13, 2025
Spatial distribution and subtype-specific expression patterns of Nectin-4 in muscle-invasive bladder cancerCsilla Olah, Lara Sichward, Boris Hadaschik, et al.
International Journal of Cancer|January 17, 2019
Circulating and tissue IMP3 levels are correlated with poor survival in renal cell carcinomaStephan Tschirdewahn, Andrej Panic, Lukas Püllen, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 21, 2025
Prognostic value of [<sup>18</sup>F]FDG- and PSMA-PET in patients evaluated for [<sup>177</sup>Lu]Lu-PSMA therapy of mCRPCTugce Telli, Leonor Lopes, Madeleine Karpinski, et al.
Langenbeck'S Archives of Surgery|December 25, 2016
Effective downsizing but enhanced intratumoral heterogeneity following neoadjuvant sorafenib in patients with non-metastatic renal cell carcinomaGencay Hatiboglu, Markus Hohenfellner, Aysenur Arslan, et al.
Pageof 27

Showing results (141-150 of 269) with videos related to

Sort By:
Pageof 27
European Urology|February 4, 2023
Small Suspicious Lymph Nodes Detected on Ultrahigh-field Magnetic Resonance Imaging (MRI) in Patients with Prostate Cancer with High Risk of Nodal Metastases: The First In-patient Study on Ultrasmall Superparamagnetic Iron Oxide-enhanced 7T MRIAnsje Fortuin, Jack van Asten, Andor Veltien, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 23, 2026
PSMA-PET response under [<sup>177</sup>Lu]Lu-PSMA therapy: Comparison of RECIST, PERCIST, PPP, adapted PCWG4 and RECIP criteriaTugce Telli, Madeleine J Karpinski, Robert Seifert, et al.
International Journal of Cancer|July 4, 2017
Cyclin K dependent regulation of Aurora B affects apoptosis and proliferation by induction of mitotic catastrophe in prostate cancerSabrina Schecher, Britta Walter, Michael Falkenstein, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 1, 2014
Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapyChristian M Zechmann, Ali Afshar-Oromieh, Tom Armor, et al.
Prostate Cancer and Prostatic Diseases|November 14, 2024
Enhancing risk stratification models in localized prostate cancer by novel validated tissue biomarkersCsilla Olah, Fabian Mairinger, Michael Wessolly, et al.
Urologie (Heidelberg, Germany)|April 13, 2026
[Update of S3 guideline on metastatic prostate cancer-guideline recommendations and expert consensus]Marc-Oliver Grimm, Christian Gratzke, Boris Hadaschik, et al.
BJU International|January 13, 2025
Spatial distribution and subtype-specific expression patterns of Nectin-4 in muscle-invasive bladder cancerCsilla Olah, Lara Sichward, Boris Hadaschik, et al.
International Journal of Cancer|January 17, 2019
Circulating and tissue IMP3 levels are correlated with poor survival in renal cell carcinomaStephan Tschirdewahn, Andrej Panic, Lukas Püllen, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 21, 2025
Prognostic value of [<sup>18</sup>F]FDG- and PSMA-PET in patients evaluated for [<sup>177</sup>Lu]Lu-PSMA therapy of mCRPCTugce Telli, Leonor Lopes, Madeleine Karpinski, et al.
Langenbeck'S Archives of Surgery|December 25, 2016
Effective downsizing but enhanced intratumoral heterogeneity following neoadjuvant sorafenib in patients with non-metastatic renal cell carcinomaGencay Hatiboglu, Markus Hohenfellner, Aysenur Arslan, et al.
Pageof 27